Ticker Report $WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI) $PACB Barclays Trims Pacific Biosciences of California (NASDAQ:PACB) Target Price to $3.00 $NFLX Netflix, Inc. (NASDAQ:NFLX) Receives $590.15 Consensus Target Price from Brokerages $SNOW Brokerages Set Snowflake Inc. (NYSE:SNOW) Target Price at $202.50 $RCI Barclays Trims Rogers Communications (NYSE:RCI) Target Price to $46.00 $CERE Cerevel Thera...
$ドックゴー(DCGO.US)$DocGo Announces Repurchases Of Common Stock And Adoption Of 10b5-1 Trading Plan For Share Repurchase Program >DCGO Dow Jones· 1 min ago
Despite a low ROE relative to the industry, DocGo increased its net income drastically over the past five years due to high earnings retention or efficient management. Experts predict future growth in the company's earnings.
Analysts express optimism for DocGo, raising EPS and revenue estimates, despite expected slower growth. However, estimates vary, with valuation ranges from د.إ58.77 to د.إ36.73 per share. The company is predicted to surpass industry growth.
$ドックゴー(DCGO.US)$DocGo Announces Record Third Quarter 2023 Results Company Raises 2023 Revenue Guidance to $615-$625 Million, up From a Previous Range of $540-$550 Million And Increases Adjusted EBITDA(1) Guidance to $50-$55 Million, up From a Previous Range of $48-$53 Million
$ドックゴー(DCGO.US)$Made a decent move at open on the good news! but wow did it peter out? will ride until end of day to see if it picks back up? unless it starts to fall into my SL? GL all.
ドックゴーに関するコメント
Ticker Report in April
$WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI)
$PACB Barclays Trims Pacific Biosciences of California (NASDAQ:PACB) Target Price to $3.00
$NFLX Netflix, Inc. (NASDAQ:NFLX) Receives $590.15 Consensus Target Price from Brokerages
$SNOW Brokerages Set Snowflake Inc. (NYSE:SNOW) Target Price at $202.50
$RCI Barclays Trims Rogers Communications (NYSE:RCI) Target Price to $46.00
$CERE Cerevel Thera...
Update
Dow Jones· 1 min ago
Earnings win
Company Raises 2023 Revenue Guidance to $615-$625 Million, up From a Previous Range of $540-$550 Million And
Increases Adjusted EBITDA(1) Guidance to $50-$55 Million, up From a Previous Range of $48-$53 Million
まだコメントはありません